✦ LIBER ✦

Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy—cytotoxicity, duration and responsiveness

✍ Scribed by Jonas Bergh

Book ID: 114315516
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 150 KB
Volume: 12
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(03)00162-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose of chemotherapy — Cytotoxicity, dur

Dose of chemotherapy — Cytotoxicity, duration and responsiveness: Can we improve present therapy results by targeted and tailored therapies?

✍ Jonas Bergh 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 369 KB

Adjuvant systemic therapies for patients

Adjuvant systemic therapies for patients with breast cancer: Endocrine responsiveness and effects of chemotherapy

✍ Marco Colleoni; Aron Goldhirsch 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Therapy of Advanced Prostate Cancer Part

Therapy of Advanced Prostate Cancer Part II: Response End Points and the Use of Chemotherapy

✍ David M. Reese; Eric J. Small 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

First-cycle absolute neutrophil count ca

First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

✍ Edgardo Rivera, M Haim Erder, Moshe Fridman, Debra Frye… 📂 Article 📅 2003 🏛 BioMed Central 🌐 English ⚖ 86 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views